MRNS Oct 2024 17.000 call
| Previous close | 0.0900 |
| Open | 1.4100 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 17.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.0900 - 1.4100 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Business WireMarinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
RADNOR, Pa., June 17, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline results from the Phase 3 double-blind, randomized, placebo-controlled RAISE trial (NCT04391569) evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). RSE, in which prolonged continuous or rapidly recurring seizures do not r
ZacksAvidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
- Zacks
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
